UroGen Pharma Ltd. - Ordinary Shares (URGN) News
Filter URGN News Items
URGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
URGN News Highlights
- URGN's 30 day story count now stands at 2.
- Over the past 11 days, the trend for URGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest URGN News From Around the Web
Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., December 08, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 17 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the |
Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years agoUroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders should be happy to see the share price up 17% in the last month. But... |
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call TranscriptUroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker […] |
UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical TrialsNet Revenue Rises as Company Advances with UGN-102 Clinical Development |
UroGen Pharma Reports Third Quarter 2023 Financial ResultsPRINCETON, N.J., November 14, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent developments. |
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic OncologyPRINCETON, N.J., November 13, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, will highlight data from two key Phase 3 trials evaluating UGN-102, an investigational treatment in development for LG-IR-NMIBC at the 2023 Society of Urologic Oncology (SUO) annual meeting, November 28-December 1 in Washington D.C. These data presentations further UroGen’s mission of developing and comme |
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023PRINCETON, N.J., November 07, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report third quarter 2023 financial results on November 14, 2023, at 8:00 AM EDT, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. |
Institutional investors own a significant stake of 50% in UroGen Pharma Ltd. (NASDAQ:URGN)Key Insights Institutions' substantial holdings in UroGen Pharma implies that they have significant influence over the... |
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024PRINCETON, N.J., October 03, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on plans for submission of a New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution. The FDA indicated that the current clinical development plan for UGN-102, which includes evaluation of du |
UroGen Pharma to Present at Upcoming Investor ConferencesPRINCETON, N.J., August 31, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in September: |